ArticleFuture virology2008
Therapeutic and prophylactic drugs to treat orthopoxvirus infections.
Article in Future virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 63 citations in OpenAlex.
- A comprehensive overview of monkeypox virus disease.Tropical medicine and health · 2026Review
- Monkeypox (Mpox), a Resurging Global Public Health Concern: An Updated Outlook Through 2025.Current issues in molecular biology · 2026Review
- Advanced strategies for the diagnosis, treatment, and vaccination of monkeypox.Journal of nanobiotechnology · 2026Review
- Monkeypox Virus Countermeasures: Vaccines, Antibodies, Drugs and Traditional Chinese Medicine.Drug design, development and therapy · 2026Review
- Monkeypox: Origin, Transmission, Clinical Manifestations, Prevention, and Therapeutic Options.Interdisciplinary perspectives on infectious diseases · 2025Review
- Synergistic effect of two human-like monoclonal antibodies confers protection against orthopoxvirus infection.Nature communications · 2024Article
- A 4-month-old male baby with an orf lesion on his nose: a rare case report.Annals of medicine and surgery (2012) · 2024Article
- Treatment and Vaccination for Smallpox and Monkeypox.Advances in experimental medicine and biology · 2024Review
- Insights on monkeypox disease and its recent outbreak with evidence of nonsynonymous missense mutation.Future science OA · 2023Review
- Current Insights into Diagnosis, Prevention Strategies, Treatment, Therapeutic Targets, and Challenges of Monkeypox (Mpox) Infections in Human Populations.Life (Basel, Switzerland) · 2023Review
- Results of the first German external quality assessment scheme for the detection of monkeypox virus DNA.PloS one · 2023Article
- Insights into monkeypox pathophysiology, global prevalence, clinical manifestation and treatments.Frontiers in immunology · 2023Review
- Monkeypox Virus Infections in Humans.Clinical microbiology reviews · 2022Review
- Clinical manifestations of human monkeypox infection and implications for outbreak strategy.Health sciences review (Oxford, England) · 2022Review
- The Emergence of Monkeypox: A Global Health Threat.Cureus · 2022Review
- The 2022 outbreak and the pathobiology of the monkeypox virus.Journal of autoimmunity · 2022Review
- Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.Antiviral research · 2014Article
- Human monkeypox.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Review
- A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012.Future virology · 2013Article
- A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.Virology journal · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
With the global eradication of smallpox in 1979, the causative agent, variola, no longer circulates in human populations. Other human poxvirus infections, such as those caused by vaccinia, cowpox virus and molluscum, are usually relatively benign in immunocompetent individuals. Conversely, monkeypox virus infections cause high levels of mortality and morbidity in Africa and the virus appears to be increasing its host range, virulence and demographic environs. Furthermore, there are concerns that clandestine stocks of variola virus exist. The re-introduction of aerosolized variola (or perhaps monkeypox virus) into human populations would result in high levels of morbidity and mortality. The attractiveness of variola as a bioweapon and, to a certain extent, monkeypox virus is its inherent ability to spread from person-to-person. The threat posed by the intentional release of variola or monkeypox virus, or a monkeypox virus epizoonosis, will require the capacity to rapidly diagnose the disease and to intervene with antivirals, as intervention is likely to take place during the initial diagnosis, approximately 10-15 days postinfection. Preimmunization of 'at-risk populations' with vaccines will likely not be practical, and the therapeutic use of vaccines has been shown to be ineffective after 4 days of infection with variola. However, a combination of vaccine and antivirals for those infected may be an option. Here we describe historical, current and future therapies to treat orthopoxvirus diseases.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.